Sign for Notice Everyday    Sign Up| Sign In| Link| English|

Our Sponsors

    Receive Latest News

    Feedburner
    Share Us


    Marketing to Medicare or Medicaid Beneficiaries - What You Can and Cannot Do

    View: 338

    Website http://www.onlinecompliancepanel.com/ecommerce/webinar/~product_id=500410?expDate=Ourglocal | Want to Edit it Edit Freely

    Category Regulatory Compliance Training; FDA Regulations Training; Compliance Training; Compliance Solutions; Regulatory News; FDA compliance; Banking and Finance Regulations; Risk Management Training; HR Compliance; Workplace Safety Regulations;

    Deadline: July 24, 2014 | Date: July 24, 2014

    Venue/Country: 38868 Salmon Ter, Fremont, U.S.A

    Updated: 2014-07-16 20:05:55 (GMT+9)

    Call For Papers - CFP

    Instructor: William Mack Copeland

    Description:

    The federal Anti-Kickback Statute ("AKS") prohibits the offer or payment, as well as the solicitation or receipt, of "any remuneration (including any kickbacks, bribe, or rebate)" in exchange for referrals. The prohibited activity is a two way street, with both the payer and the receiver equally culpable. What constitutes "any remuneration," however, is a gray area. While the statute provides that remuneration includes "any kickback, bribe or rebate," it does not define these terms. Further, there is a prohibition against remuneration "directly or indirectly, overtly or covertly, in cash or in kind."

    Violation of the AKS is a felony with maximum fine of $25,000 and imprisonment up to five years, or both. Conviction results in automatic exclusion from federal health care programs. The Office of the Inspector General ("OIG") may initiate administrative proceedings based on a violation of the AKS and impose Civil Monetary Penalties ("CMPs") or exclude the offending party from federal health care programs.

    The AKS includes both statutory exceptions and regulatory safe harbors. The safe harbors relevant to a discussion of marketing to Medicare/Medicaid beneficiaries include: (1) waiver of beneficiary coinsurance and deductibles by hospitals and selected other providers, or (2) increased coverage, reduced cost sharing or reduced premiums offered by health plans.

    The Civil Monetary Penalties Law ("CMP Law") prohibits offering or transferring remuneration to a Medicare/Medicaid beneficiary that the person knows or should know is likely to induce selection of a particular provider, for which payment may be made in whole or part by Medicare or Medicaid. "Remuneration" is defined as any transfer of items or services for free or other than fair market value. Violation of this CMP may be penalized by a civil fine of $10,000.00 per item or service. In addition, the OIG may administratively exclude the party from federal health care programs.

    This webinar will scrutinize these laws with a view to understanding these illegal inducements and changes made by Obamacare. The program will also examine guidance provided by the Department of Health and Human Services and the OIG. Finally, the program will look at potential risk areas.

    The Medicare/Medicaid Fraud and Abuse Anti?Kickback Statute (the "Statute") is alive, still with us and as viable as ever. The Statute provides that the offer or payment, as well as the solicitation or receipt, of "any remuneration" in exchange for referrals of any good, facility, service, or item for which payment may be made in whole or in part under Medicare/Medicaid is prohibited. Likewise, the Civil Monetary Penalties Law prohibits offering or transferring remuneration to a Medicare/Medicaid beneficiary that the person knows or should know is likely to induce selection of a particular provider.

    Why Should you Attend:

    If your organization, be it a hospital, physician practice, DME provider, or any other provider offering healthcare services or supplies, engages in marketing its product or services, care must be taken to ensure that the organization does not run afoul of the Anti-Kickback Statutke. This program will review not only the Statute itself, and the safe harbors, but will also critique the case law, OIG advisory opinions, and OIG compliance guidance to help you understand what you can and cannot do with engaging in healthcare marketing.

    When you finish this program, you should have a good understanding of what you can and cannot do with regard to marketing activities. The penalties for not conducting a marketing program correctly can be severe, including exclusion, civil monetary penalties and even criminal prosecution.

    Attend this webinar and learn how to protect yourself and your organization.

    Objectives of the Presentation:

    To provide the attendee with an understanding of the risk of marketing to Medicare and Medicaid beneficiaries and the potential for violating the federal Anti-Kickback Statute and/or the Civil monetary penalties law. The presentation will also provide attendees the tools necessary to protect themselves and their organizations from federal and state enforcement efforts under these law.

    Who can Benefit:

    Hospital executives, particularly CEOs, COOs, CFOs, CNOs, and CMOs

    Nursing home executives

    Physicians

    Physician practice managers

    Durable medical equipment supplier executives

    Other healthcare provider executives.

    Quick Contact

    http://www.onlinecompliancepanel.com/ecommerce/webinar/~product_id=500410?expDate=Ourglocal

    Toll free: +1-510-857-5896

    Email:?webinaratonlinecompliancepanel.com

    OnlineCompliancePanel LLC,

    38868 Salmon Ter,

    Fremont, CA 94536, USA


    Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
    Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.